 |
|
|
|
|
Management Team
Argos' senior management has extensive pharmaceutical and biotechnology
industry experience including the clinical development, regulatory approval
and commercial introduction of oncology products, as well as the manufacturing
scale-up and launch of "blockbuster" products.
|
| Dr. John Bonfiglio, Ph.D., M.B.A. |
President, Chief Executive Officer |
| Timothy W. Trost, C.P.A. |
Vice President, Chief Financial Officer |
| Frederick M. Miesowicz, Ph.D. |
Chief Operating Officer |
| Lothar H. Finke, M.D. |
Chief Medical Officer and Vice President, Regulatory Affairs |
| Charles A. Nicolette,
Ph.D.
|
Chief Scientific Officer, Research
and Development |
| Jeffrey D. Abbey,
M.B.A., J.D. |
Vice President, Business Development |
|
JOHN N. BONFIGLIO, PH.D., M.B.A.
President and Chief Executive Officer
John Bonfiglio joined Argos Therapeutics
in 2007. Before joining
Argos, Dr. Bonfiglio was President and CEO of Immune Response Corporation,
where he led that company’s business development strategy and oversaw
multiple clinical trials, manufacturing and the development of biologic
immuno-stimulatory therapeutic agents. Prior to joining Immune Response,
Dr. Bonfiglio served as Chief Operating Officer and Executive Vice President
of Cypress Bioscience, where his responsibilities included business development,
marketing, research and development, clinical development, strategic direction,
and budgeting. He has also served as President and CEO of Peregrine
Pharmaceuticals, as Director of the Strategic Business Unit at Baxter Healthcare
Corporation, and as Director of Business Planning at Allergan. Dr.
Bonfiglio holds an M.B.A. from Pepperdine University and received his Ph.D.
and Masters in Organic Chemistry from University of California – San
Diego. He received a Bachelors degree in Chemistry from the State University
of New York – Stony Brook.
return to top
Timothy W. Trost, CPA
Vice President & Chief Financial Officer
Timothy Trost joined Argos Therapeutics in 2002. Prior to joining Argos,
Mr. Trost most recently served as Senior Vice President & Chief Financial
Officer of InteCardia, Inc., a venture-backed cardiology development company
sold to Syncor International in August 2001. Prior to InteCardia, he served
as Senior Vice President of Corporate Development and later as Executive
Vice President and Chief Financial Officer of Coastal Physician Group,
Inc., a contract provider of emergency room physicians. Prior to that,
Mr. Trost served as Vice President of Finance/Controller of Morganite North
America, Inc., the U.S. holding company for The Morgan Crucible Company
plc. He began his professional career with a total of twelve years (in
four offices) at the international accounting and consulting firm of Price
Waterhouse. Mr. Trost holds a degree in accounting from the University
of Illinois at Urbana-Champaign and is a Certified Public Accountant.
return to top
Frederick M. Miesowicz, Ph.D.
Chief Operating Officer
Frederick Miesowicz joined Argos Therapeutics in 2003. Prior to this,
Dr. Miesowicz was the Vice President of U.S. Operations for Gamida-Cell,
a stem cell company. He was Senior Vice President and General Manager of
Hybridon Specialty Products. He served as Vice President and General Manager
of Cellcor, a subsidiary of Cytogen, Inc., from 1995 to 1998, where he
directed all operations related to Cellcor’s cellular immunotherapy
programs. He also served as Senior Vice President of Scientific Affairs
at Cellcor from 1992 to 1995. Dr. Miesowicz has an extensive background
in cellular therapies and medical devices. Prior to joining Cellcor, he
managed the U.S. and European SteriCell Division of Terumo Medical Corporation
after it was acquired from DuPont, and was with E.I. DuPont de Nemours & Company
for over 14 years managing both immunotherapy and immunodiagnostic R&D
groups. Dr. Miesowicz holds a B.S. degree in Chemistry from Siena College
and received a Ph.D. in Chemistry from Harvard University.
return to top
Lothar H. Finke, M.D.
Chief Medical Officer and Vice President, Regulatory Affairs
Lothar Finke joined Argos Therapeutics in 2004 to lead its clinical development
and regulatory affairs efforts for a broad range of therapies. Dr. Finke
has nine years of oncology development experience in the pharmaceutical
and biotech industry – both in Europe and the United States. Additionally,
he has six years of clinical experience in surgical oncology and 10 years
of experience in molecular and cell biology. Prior to joining Argos, Dr.
Finke worked for a number of companies, including EMD Pharmaceuticals,
Lexigen Pharmaceuticals and Merck KGaA. Academically, Dr. Finke worked
at the Max Delbrueck Center for Molecular Medicine, the Basel Institute
for Immunology, Ruprecht Karls University of Heidelberg and Philipps University,
Marburg/Lahn, Germany. As part of his industry experience, he is trained
and experienced in regulatory affairs, drug safety and clinical development
relevant to Europe, the United States, Canada and Japan. Dr. Finke received
both his medical degree and cell biology doctorate from Philipps University
of Marburg in Lahn, Germany.
return to top
Charles A. Nicolette, Ph.D.
Chief Scientific Officer , Research and Development
Charles Nicolette joined Argos Therapeutics in 2003. Dr. Nicolette has extensive
experience in the field of cancer immunotherapy and is the inventor on dozens
of patent applications and issued patents relating to the development of personalized
immunotherapeutics for cancer and infectious diseases. He was formerly the Director
of Antigen Discovery at Genzyme Molecular Oncology where he developed SPHERE
technology, the subject of one of the largest biotechnology deals ever done in
the field of tumor antigen discovery. He is an expert in cellular immunology
and brings substantial immunological sophistication to Argos. Dr. Nicolette received
his Ph.D. in biochemistry and cellular and developmental biology from the State
University of New York at Stony Brook, completing his doctoral dissertation and
post-doctoral fellowship at Cold Spring Harbor Laboratory.
return to top
Jeffrey D. Abbey, M.B.A., J.D.
Vice President, Business Development
Jeffrey Abbey joined Argos Therapeutics in September 2002. Before joining
Argos, Mr. Abbey was Vice President of Business Development and Finance
for Internet Appliance Network (IAN), a venture-backed information technology
company based in New York City. Prior to joining IAN, he was a partner
in Eilenberg and Krause, a boutique corporate law firm, where he acted
as business counsel for a number of life sciences and other emerging technology
companies. Mr. Abbey has extensive experience in structuring and negotiating
licenses, joint ventures and other technology transfer agreements, as well
as mergers, acquisitions and financing transactions. He holds an A.B. in
Mathematical Economics from Brown University and received an M.B.A. and
J.D. from the University of Virginia.
return to top
|
|
 |
|
